CD5L Polyclonal Antibody

Cat.#: 164773

Special Price 174.2 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    CD5L Polyclonal Antibody
  • Documents
  • Description
    Polyclonal antibody to CD5L
  • Tested applications
    WB
  • Species reactivity
    Human, Mouse
  • Alternative names
    CD5L antibody; AIM antibody; API6 antibody; CT-2 antibody; PRO229 antibody; SP-ALPHA antibody; Spalpha antibody; hAIM antibody; CD5 antigen-like antibody
  • Isotype
    Rabbit IgG
  • Preparation
    Antigen: Recombinant fusion protein containing a sequence corresponding to amino acids 20-347 of human CD5L (NP_005885.1).
  • Clonality
    Polyclonal
  • Formulation
    PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
  • Storage instructions
    Store at -20℃. Avoid freeze / thaw cycles.
  • Applications
    WB 1:500 - 1:2000
  • Validations

    Western blot - CD5L Polyclonal Antibody

    Western blot - CD5L Polyclonal Antibody

    Western blot analysis of extracts of various cell lines, using CD5L antibody at 1:1000 dilution._Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution._Lysates/proteins: 25ug per lane._Blocking buffer: 3% nonfat dry milk in TBST._Detection: ECL Basic Kit ._Exposure time: 70s.

  • Background
    Secreted protein that acts as a key regulator of lipid synthesis: mainly expressed by macrophages in lymphoid and inflammed tissues and regulates mechanisms in inflammatory responses, such as infection or atherosclerosis. Able to inhibit lipid droplet size in adipocytes. Following incorporation into mature adipocytes via CD36-mediated endocytosis, associates with cytosolic FASN, inhibiting fatty acid synthase activity and leading to lipolysis, the degradation of triacylglycerols into glycerol and free fatty acids (FFA). CD5L-induced lipolysis occurs with progression of obesity: participates in obesity-associated inflammation following recruitment of inflammatory macrophages into adipose tissues, a cause of insulin resistance and obesity-related metabolic disease. Regulation of intracellular lipids mediated by CD5L has a direct effect on transcription regulation mediated by nuclear receptors ROR-gamma (RORC). Acts as a key regulator of metabolic switch in T-helper Th17 cells. Regulates the expression of pro-inflammatory genes in Th17 cells by altering the lipid content and limiting synthesis of cholesterol ligand of RORC, the master transcription factor of Th17-cell differentiation. CD5L is mainly present in non-pathogenic Th17 cells, where it decreases the content of polyunsaturated fatty acyls (PUFA), affecting two metabolic proteins MSMO1 and CYP51A1, which synthesize ligands of RORC, limiting RORC activity and expression of pro-inflammatory genes. Participates in obesity-associated autoimmunity via its association with IgM, interfering with the binding of IgM to Fcalpha/mu receptor and enhancing the development of long-lived plasma cells that produce high-affinity IgG autoantibodies (By similarity). Also acts as an inhibitor of apoptosis in macrophages: promotes macrophage survival from the apoptotic effects of oxidized lipids in case of atherosclerosis. Involved in early response to microbial infection against various pathogens by acting as a pattern recognition receptor and by promoting autophagy.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"